North America Anticoccidial Drugs Market - Global Trends and Forecasts - (2020 - 2025)

The market is segmented By Drug Type (Ionophore Anticoccidials and Chemical Derivative Anticoccidials), By Animal, and Geography.

Market Snapshot

anticoccidial drugs market
Study Period: 2017-2025
Base Year: 2019
CAGR: 4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

North America Anticoccidial Drugs Market is expected to register a CAGR of 4% during the forecast period. Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.

Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.

Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.

However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.

Scope of the report

Coccidiosis is one of the most frequent and prevalent parasitic diseases among domesticated animals and its symptoms include weight loss, mild intermittent to severe diarrhoea, faeces containing mucus or blood, dehydration, and decreased breeding. Coccidiosis is caused by single-celled parasites (protozoa) called Eimeria, which undergo a simple life cycle in the gut. Any drug used to combat the progression of coccidiosis in birds or animals, both food-producing and non-food producing, is termed as an anticoccidial.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Ionophore Anticoccidial segment dominates the North America Anticoccidial Drugs Market

A major breakthrough in the prevention of coccidiosis through feed medication occurred in 1972, with the launch of the first polyether ionophore anticoccidial, monensin. This type of anticoccidial agent has been commonly referred to as ionophores, a term derived from their general chemical structure. Ionophores are the fermentation products of Streptomyces and other fungi species.

Furthermore, these drugs are widely used for the prevention of coccidiosis, due to its broad-spectrum activity against the majority of pathogenic species of coccidian and lack of development of drug resistance. Each has a different mode of action and no significant resistance has been developed. These drugs are commonly added to the starter and grower feeds, but not to the finisher or withdrawal feeds.

Furthermore, when the same ionophore anticoccidial is added to the starter and grower feeds, it is known as a straight program. In 2017, the US Food and Drug Administration reported that 82% of all domestic sales and distribution of non-medically important antimicrobials were from ionophores, amounting to 4,394,850 kilo gram.

As a result of the aforementioned factors, the ionophore anticoccidial segment is expected to experience healthy growth during the forecast period.

NewKey trend_Antico.png

Competitive Landscape

The North America Anticoccidial Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Zoetis Animal Healthcare, Phibro Animal Health Corporation, Huvepharma, Elanco, Ceva Animal Health Inc., MSD Animal Health, Vetoquinol SA, Impextraco NV.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1  Increased Incidence of Coccidiosis

      2. 4.2.2 Advancements in Veterinary Healthcare

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Treatment Options in the Market

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Ionophore Anticoccidials

      2. 5.1.2 Chemical Derivative Anticoccidials

    2. 5.2 By Animal

      1. 5.2.1 Poultry

      2. 5.2.2 Swine

      3. 5.2.3 Fish

      4. 5.2.4 Cattle

      5. 5.2.5 Companion Animals

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 Zoetis Animal Healthcare

      2. 6.1.2 Phibro Animal Health Corporation

      3. 6.1.3 Huvepharma

      4. 6.1.4 Elanco

      5. 6.1.5 Ceva Animal Health Inc.

      6. 6.1.6 MSD Animal Health

      7. 6.1.7 Vetoquinol SA

      8. 6.1.8 Impextraco NV

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Anticoccidial Drugs Market market is studied from 2017 - 2025.

The North America Anticoccidial Drugs Market is growing at a CAGR of 4% over the next 5 years.

Phibro Animal Health Corporation, Huvepharma, Zoetis Animal Healthcare, Elanco., Boehringer Ingelheim GmbH are the major companies operating in North America Anticoccidial Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!